Drug

Ferumoxytol

Regulatory activity · MHRA

Emerging researchLate-stage development

Also known as FERUMOXYTOL NON-STOICHIOMETRIC MAGNETITE, Feraheme.

RxNorm473387UNIICLH5FT6412

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Single-center, Evaluator-blinded Clinical Study of Polysaccharide Superparamagnetic Iron Oxide Injection for Magnetic Resonance Venography in Patients With Venous System Diseases

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A First-in-Human Clinical Trial of Pharmacologic Ascorbate and Ferumoxytol Combined With Concomitant Temozolomide and External Beam Radiation Therapy for Newly Diagnosed Glioblastoma

Clinical trial2026-07-20Results posted · ClinicalTrials.gov

A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia

Clinical trial2026-06-30Results posted · ClinicalTrials.gov

Omega-3 Fatty Acids and Myocardial Inflammation in HFpEF: Preliminary Data and Next Steps

Clinical trial2026-06-09Results expected Q2 2027 · ClinicalTrials.gov

Trial of Darbepoetin Plus Slow-release Intravenous Iron to Decrease Transfusions and Improve Iron Status and Neurodevelopment in Preterm Infants

Clinical trial2026-05-26Results expected Q1 2027 · ClinicalTrials.gov

Ferumoxytol Enhanced Hippocampal Vascular Imaging in Epilepsy

Clinical trial2026-05-08Results expected Q3 2029 · ClinicalTrials.gov

A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Clinical trial2026-04-17Results expected Q3 2026 · ClinicalTrials.gov

Phase II, Open Label, Randomized, Multicenter Trial Comparing Noncontrast MRA vs. Ferumoxytol Vascular Enhanced MRI for Detection of Stenosis or Occlusion of the Aortoiliac and Superficial Femoral Arteries in PAD Subjects Scheduled for DSA

Clinical trial2026-04-16Results posted · ClinicalTrials.gov

Advanced MRI for Visualization and Quantification of the Tumor Immune Microenvironment (TIME) in Glioblastoma

Clinical trial2026-03-10Results expected Q4 2028 · ClinicalTrials.gov

Drug Safety Update: Ferumoxytol: risk of serious hypersensitivity reactions—contraindicated if any drug allergy; administer via infusion

Regulatory2014-12-11MHRA

Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min.

Research2013-09-09American journal of hematology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Ferumoxytol

Aliases & brands

FERUMOXYTOL NON-STOICHIOMETRIC MAGNETITEFeraheme

RxNorm CUI

473387

UNII

CLH5FT6412

Regulatory jurisdictions

mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

MHRA

Total events

mhraMedicines and Healthcare products Regulatory Agency· 1 event

2014-12-11Safety communicationSafety

Drug Safety Update: Ferumoxytol: risk of serious hypersensitivity reactions—contraindicated if any drug allergy; administer via infusion

Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).